Characterization of Krüppel-like factor 3 expression in T lymphocytes in septic mice

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background Krüppel-like factor 3 (KLF3) may be involved in the regulation of inflammatory responses and lymphocyte function. Moreover, immune dysfunction in sepsis involves both hyperinflammatory responses and immunosuppression. However, studies on T-lymphocyte KLF3 expression characteristics in sepsis are lacking. Methods We induced sepsis in mice through cecal ligation and puncture (CLP) and evaluated their survival rate over 7 days. To identify the immune status of the septic mice, we assessed their cytokine levels, organ damage scores, and splenic T-lymphocyte phenotype. Finally, KLF3 expression in T lymphocytes was detected through flow cytometry. Results Over the 7 days of observation, septic mice demonstrated 64.7% mortality. In the early stages after CLP, the proinflammatory and anti-inflammatory cytokine levels increased rapidly, multiple organ damage occurred, and splenic T lymphocytes became activated (with an increase in the proportions of CD69 + cells and mean fluorescence intensity for CD71). However, the proportion of KLF3 + T lymphocytes decreased. Subsequently, cytokine levels and lymphocyte activation decreased. An increase in cell apoptosis led to a substantial loss of T lymphocytes. Considering the continual elevations in serum interleukin 10 and interleukin 6 levels and worsening severe organ damage, the septic mice may have entered a state of chronic inflammation and immunosuppression, with a simultaneous increase in KLF3 expression in T lymphocytes, in the later stages after CLP. Conclusions In septic mice, T-lymphocyte KLF3 expression decreased in the early stage after CLP (i.e., systemic inflammatory response and T-lymphocyte activation stage) but increased in the later stage (i.e., chronic inflammation and immunosuppression stage). As such, KLF3 may be a promising target for dynamic immune monitoring and immunomodulatory therapy for sepsis.

Article activity feed